Patents Examined by Avis M. Davenport
  • Patent number: 6326467
    Abstract: Certain toxic compounds (T) such as, for example, compounds based upon diphtheria toxin, ricin toxin, pseudomonas exotoxin, &agr;-amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the gonadotrophs of the animal's anterior pituitary gland. Hence such compounds may be used to sterilize such animals and/or to treat certain sex hormone related diseases.
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: December 4, 2001
    Assignee: Colorado State University Research Foundation
    Inventors: Torrance M. Nett, Leonard Michael Glode, Maciej Wieczorek, Paul J. Jarosz
  • Patent number: 6323176
    Abstract: The present invention relates to compounds of formula where R5 is a sugar moiety. The compounds are useful in inhibiting fungal and parasitic activity and infections.
    Type: Grant
    Filed: February 5, 1999
    Date of Patent: November 27, 2001
    Assignee: Eli Lilly and Company
    Inventors: James Andrew Jamison, Michael John Rodriguez, Venkatraghavan Vasudevan
  • Patent number: 6323317
    Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: November 27, 2001
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
  • Patent number: 6316414
    Abstract: The present invention encompasses novel peptides that are agonists to somatostatin and the use of the agonists for treatment of cancer. The invention particularly relates to the design and synthesis of novel analogs of somatostatin incorporating &agr;, &agr;-dialkylated amino acids in a site specific manner. The invention encompasses methods for the generation of these peptides, compositions containing the peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: November 13, 2001
    Assignee: Dabur Research Foundation
    Inventors: Anand C. Burman, Sudhanand Prasad, Rama Mukherjee, Manu Jaggi, Anu T. Singh, Archna Mathur
  • Patent number: 6316410
    Abstract: The invention disclosed relates to analogues of human parathyroid hormoneh(PTH) which have increased activities in bone restoration, and increased bioavailablities. The analogues described are either single cyclic (1-28) or (1-29) analogues, or double cyclic (1-28) to (1-31) analogues. The single cyclic analogues are cyclised between amino acid pairs R22 and R26. The double cyclic analogues are cyclised between amino acid pairs 13 and 17, and 22 and 26. Various substitutions of the natural residues for other amino acids are also described. For example, the natural Lys27 residue may be substituted by Leu. Typically, these novel analogues have enhanced abilities to stimulate adenyl cyclase activity in rat osteosarcoma cells, and show increased activities in bone restoration using the ovariectomized rat model.
    Type: Grant
    Filed: September 22, 1999
    Date of Patent: November 13, 2001
    Assignee: National Research Council of Canada
    Inventors: Jean-René Barbier, Paul Morley, James F. Whitfield, Gordon E. Willick
  • Patent number: 6313095
    Abstract: Disclosed herein are tetrapeptide derivatives of the formula X—NH—CHR1—C(W1)—NR2—CH[CH2C(O)—Y]—C(W2)—NH—CH[CR3(R4)—COOH]—C(W3)—NH—CHR5—Z wherein X is a terminal group, for example, alkanoyl or phenylalkanoyl radicals, R1 and R5 are selected from amino acid or derived amino acid residues, R2 is hydrogen, alkyl or phenylalkyl, R3 and R4 are hydrogen or alkyl or R3 and R4 are joined to form a cycloalkyl, W1, W2and W3 are oxo or thioxo, Y is, for example, an alkoxy or a monosubstituted or disubstituted amino, and Z is a terminal unit, for example, hydrogen, COOH or CH2OH. The derivatives are useful for treating herpes infections.
    Type: Grant
    Filed: October 6, 1994
    Date of Patent: November 6, 2001
    Assignee: Boehringer Ingelheim (Canada), Ltd.
    Inventors: Julian Adams, Pierre Louis Beaulieu, Robert Déziel, Neil Moss
  • Patent number: 6313093
    Abstract: Disclosed is a method for transporting neurologic therapeutic agents to the brain by means of the olfactory neural pathway and a pharmaceutical composition useful in the treatment of brain disorders.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: November 6, 2001
    Assignee: Chiron Corporation
    Inventor: William H. Frey, II
  • Patent number: 6310041
    Abstract: The present invention is directed to a series of complementary peptides for the pro-gly-pro sequence as antagonists of polymorphonuclear leukocyte chemoattractants. Also provided are applications of such peptides for treating alkali-injuried eyes and other types of diseases.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: October 30, 2001
    Assignee: Fornix Biosciences N.V.
    Inventors: Jeffrey Lynn Haddox, Roswell Robert Pfister, James Edwin Blalock, Matteo Villain
  • Patent number: 6310177
    Abstract: Methods for using modulating agents to enhance or inhibit occludin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase vasopermeability. The modulating agents comprise at least one occludin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the occludin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: October 30, 2001
    Assignee: Adherex Technologies, Inc.
    Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
  • Patent number: 6310036
    Abstract: Disclosed is a novel tissue adhesive technology comprising a combination of ultrasonically treated proteins including collagen and albumin which form a viscous material that develops adhesive properties when chemically cross-linked. A novel new cross-linking agent with surprisingly stable properties was developed in association with the tissue adhesive described and claimed herein and is considered to be within the scope of the present invention. This new cross-linking agent is a product of reacting glutaraldehyde with amino acids or peptides and allowing the reaction to proceed to completion. This chemical cross-linker is mixed with the ultrasonically treated proteins, allowed to react for a pre-determined time, then used to seal large surface areas of vigorously bleeding tissues including, but not limited to, the liver, lungs and major vascular systems in patients with and without bleeding disorders. This same tissue adhesive has proven to work well in sealing suture sites to prevent leakage.
    Type: Grant
    Filed: January 9, 1999
    Date of Patent: October 30, 2001
    Assignee: Last Chance Tissue Adhesives Corporation
    Inventor: David A. Browdie
  • Patent number: 6307017
    Abstract: A linear (i.e., non-cyclic) analog of biologically active amphibian bombesin, mammalian gastrin-releasing peptide (GRP), or mammalian growth hormone releasing factor (GRF), having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell. Cleavage of a peptide bond in the active site of naturally occurring bombesin, GRP, or GRF is unnecessary for in vivo biological activity. The analog has one of the following modifications: (a) a deletion of an amino acid residue within the active site and a modification of an amino acid residue outside of the active site, (b) a replacement of two amino acid residues within the active site with a synthetic amino acid, a &bgr;-amino acid, or a &ggr;-amino acid residue, or (c) a non-peptide bond instead of a peptide bond between an amino acid residue of the active site and an adjacent amino acid residue.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: October 23, 2001
    Assignees: Biomeasure, Incorporated, The Administrators of the Tulane Educational Fund
    Inventors: David H. Coy, Jacques-Pierre Moreau, Sun Hyuk Kim
  • Patent number: 6303573
    Abstract: The present invention provides a heart homing peptide that contains the amino acid sequence GGGVFWQ (SEQ ID NO: 2); HGRVRPH (SEQ ID NO: 3); VVLVTSS (SEQ ID NO: 4); CLHRGNSC (SEQ ID NO: 9); or CRSWNKADNRSC (SEQ ID NO: 10) and further provides conjugates in which a heart homing peptide is linked to a moiety such as a therapeutic agent. The conjugates of the invention are useful for treating cardiovascular diseases such as atherosclerosis and restenosis.
    Type: Grant
    Filed: June 7, 1999
    Date of Patent: October 16, 2001
    Assignee: The Burnham Institute
    Inventors: Erkki Ruoslahti, Deidre A. MacKenna
  • Patent number: 6303579
    Abstract: The invention provides pharmaceutical compositions containing calpain inhibitors and methods of using these calpain inhibitors to prevent or ameliorate ocular neural tissue disease or damage.
    Type: Grant
    Filed: April 5, 1999
    Date of Patent: October 16, 2001
    Assignee: Alcon Laboratories, Inc.
    Inventors: Iok-Hou Pang, Michael A. Kapin, Louis DeSantis, Jr.
  • Patent number: 6291431
    Abstract: Methods and compositions are provided for the treatment of staphylococcal infections.
    Type: Grant
    Filed: April 2, 1998
    Date of Patent: September 18, 2001
    Assignees: Panorama Research, The Regents of the University of California
    Inventors: Naomi Balaban, James W. Larrick, Susan C. Wright
  • Patent number: 6288040
    Abstract: The invention relates to medicament excipient particles which are suitable for tissue-specific application of a medicament, especially to the central nervous system (CNS). The invention particles can be loaded with or be free pf the active substance. At least one detection protein is bonded to the particle surface or alternatively, the particle surface is modified in such a way that a detection protein bonds with it on contact.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: September 11, 2001
    Assignee: DSS Drug Delivery Service Gesellschaft zur Forderung der Foshung In Phamazeutischer Technologi und Biopharmazie mbH
    Inventors: Ranier H. Müller, Martin Lück, Jörg Kreuter
  • Patent number: 6288026
    Abstract: The invention concerns a process for treating systemic inflammatory response syndrome (SIRS), intensive care requiring conditions, viral diseases, Colitis ulcerosa, Crohn's disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis, infectious hospital polyresistance conditions of viral and bacterial sources (infections hospitalismus), bronchial asthma, kidney and urethral infections, migraines, rheumatoid arthritis, osteoporosis Sudeck, acute and chronic inflammations, venal and arterial inflammations, acute and chronic exhaustion conditions, tumors, muscle shrinkage diseases, hemorrhoids, chemically induced heart diseases, hypertonia, aging phenomena, acute and chronic pain conditions, spastics, polyneuropathies, prostate neoplasms, hair loss, impotence, neurodermitis, cervical syndrome, tissue traumas, and amyotropic lateral sclerosis (Lou Gehrig's disease), which comprises administering to a patient in need therefor an effective amount of Paravac composition which can suitab
    Type: Grant
    Filed: February 23, 2000
    Date of Patent: September 11, 2001
    Inventors: Heinrich Exner, Peter Klose
  • Patent number: 6287759
    Abstract: A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 11, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Sergei A. Tsarev, Suzanne U. Emerson, Robert H. Purcell
  • Patent number: 6288025
    Abstract: Psoriasis may be treated by topical administration of a urokinase inhibitor, such as PAI-2, or a combination of protease inhibitors, such as PAI-2 with other serine protease inhibitors and/or with protease inhibitors such as inhibitors of metalloproteinases, acid proteases, and thiol proteases.
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: September 11, 2001
    Assignee: Biotech Australia Pty Limited
    Inventors: Clive Leighton Bunn, Phillip John Sharp
  • Patent number: 6284733
    Abstract: The invention relates to a modified tandem LHRH-peptide vaccine preparation in which the amino acid glycine at position (6) of one or both LHRH decapeptides that constitute the tandem unit is substituted by a dextrorotatory amino acid that contains a side chain to which a carrier compound can be coupled. In addition, the tandem LHRH-peptide can be brought into a tandem-dimer form which is also suitable for producing a vaccine that is effective against LHRH (luteinizing hormone releasing hormone) also referred to as GnRH (gonadotropin-releasing hormone), for immunological castration, to inhibit or affect reproductive functions or to affect behaviour in vertebrates in general and in domesticated animals and man in particular.
    Type: Grant
    Filed: March 22, 1999
    Date of Patent: September 4, 2001
    Assignee: DLO Instituut Voor Dierhouderij en Diergezondheid
    Inventors: Robert Hans Meloen, Hendrica Berendina Oonk
  • Patent number: 6284725
    Abstract: Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the glucagon-like peptide-1. The invention relates to both the method and compositions for such treatment.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: September 4, 2001
    Assignee: BioNebraska, Inc.
    Inventors: Thomas R. Coolidge, Mario R. W. Ehlers